Lipitor (atorvastatin) was the top-selling prescription medication in the United States in 2010, earning its manufacturer, Pfizer, more than $7 billion in total revenue. The overall market for prescription lipid-lowering drugs continues to grow; this drug class had greater prescription volume than any other class in 2010, with statins dominating the market. Lipitor's patent expired in June 2011, and the first generic version entered the market on November 30.
Click sobre imagen para ampliar
To explore the possible economic impact of the availability of generic atorvastatin, we examined past trends in statin use to project potential future cost savings. The similar scenario of the market entry of generic simvastatin when the patent for Zocor (Merck) expired in 2006 provided a historical example to guide our projections, including information on timing of generic-product use, changes in the average prices of generic and brand-name products, and the extent to which patients switched to other drugs within the statin class. We also considered the effect that the aging of the population would have on the demand for statins. We believe our estimates of cost savings with generic atorvastatin are conservative, given the historical simvastatin patterns. When generic simvastatin entered the market, Zocor had immense competition from Lipitor, a high-potency statin, whereas Lipitor has no competitor that offers an advantage over it. Crestor (rosuvastatin) (AstraZeneca), a new higher-potency statin, has not been shown to be superior to Lipitor in reducing risk and so is unlikely to command a large share of the market. In the United States, Lipitor, Crestor, and generic simvastatin accounted for 77% of the statin market in 2009. Lipitor's market share dropped from 44% in 2006 to 26% in 2009, when simvastatin dominated the statin market, with a market share of 41%.
The current market shares of Lipitor and simvastatin are estimated at 21% and 51%, respectively. According to our assumptions, generic atorvastatin will dominate the statin market as a result of patients' switching to it from simvastatin and from Crestor, and it will have an estimated market share of 44% by 3 years after market entry (see graph). Generic atorvastatin's lower price makes it less costly than Crestor and competitively priced with generic simvastatin, and atorvastatin doesn't pose the risk of myopathy that high-dose simvastatin does.
The historical trends show that the price of generic simvastatin 1 month after market entry was 84% of the average brand-name price in the quarter before that entry, 81% after 6 months, and about 40% after 12 and 36 months. On the basis of these trends, we project that the ratio of the price of generic atorvastatin to that of pregeneric brand-name Lipitor will be 0.82 at the time of market entry and 0.49 after the 6-month exclusivity period that is granted to the first generic product. The overall cost savings from the availability of generic atorvastatin are projected to reach $4.5 billion annually by 2014, equivalent to 23% of total expenditures on statins in that year. When the aging of the population is factored in, the projected cost savings increase by $10 million, $20 million, and $30 million annually in 2012, 2013, and 2014, respectively.Ver:
Entradas
No hay comentarios:
Publicar un comentario